Sunday, April 17, 2011
New Patient Safety Initiative Stresses Teamwork, Not Blame - Dr Berwick/Medscape "Doing It Right Costs Less Than Doing It Wrong"
"....Both Dr. Berwick and Sebelius said that the new program works hand in hand with the new healthcare act (U.S.) , which measures and pays for the kind of high-quality, coordinated care envisioned in the initiative. In addition, similar to the Affordable Care Act, Partnership for Patients addresses the problem of runaway healthcare costs.
"The options are either to cut care or improve care," said Dr. Berwick. "I'm against cutting. I'm for improving. Doing [healthcare] right costs less than doing it wrong."
For more information about Partnership for Patients, visit the HHS Web site.
MJA Insight: : The cost of negligent opinion (expert opinion) WHAT should happen if an expert witness is negligent?
"....Professor Young suggested that the National Health and Medical Research Council (NHMRC) could prioritise funding for specific cancers. “The NHMRC needs to take a more strategic view as to where they place the funds, and where they create the incentive for specific cancers,” he said.
He said this would encourage researchers to study the underrepresented cancers. “In my view, researchers go to where they can get the money and not necessarily to where the problems are, and I think this paper proves that,” he said...."
Dr Annette Katelaris:
"... the National Cancer Institute in the United States is planning to create a “cross-disease panel” that will establish priorities for funding and coordination of clinical trials."
Note: The Oncologist has some very good articles/worthwhile spending time searching for items of interest, all typically written in 'plain english'
Complimentary access now available!
Trastuzumab (Herceptin) Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities -- The Oncologist
Note: Trastuzumab is also known as Herceptin "Based on these considerations, it would be interesting if Extra and colleagues could reanalyze their data by distinguishing patients stopping trastuzumab according to whether or not they had "equal opportunities" to patients continuing trastuzumab beyond progression." (The Oncologist) Editor's note: Dr. Extra was invited to reply but declined comment.